Bioxyne Limited Announces Expiry of 90,833 BXNAC Performance Rights Due to Unmet Vesting Conditions

Reasons Behind the Lapse of 90,833 BXNAC Performance Rights

As detailed in the company’s filing under ASX Listing Rule 3.10.3E and Appendix 3H, the 90,833 BXNAC Performance Rights did not lapse due to expiry without exercise or cancellation via buy-back or capital reduction. Instead, they lapsed because the conditional rights’ vesting criteria were not met or became impossible to satisfy. This distinction indicates that specific performance targets tied to this tranche were not achieved within the required timeframe.

Performance rights in Australian listed companies typically grant ordinary shares only if certain performance benchmarks—such as revenue goals, share price targets, or strategic milestones—are attained. When these conditions fail, the rights lapse without value. Bioxyne confirmed no consideration was paid to holders, aligning with standard practice for lapsed rights under employee incentive schemes.

Cessation Date and Timing of Market Notification

The official cessation date for these performance rights is 30 June 2026, although the market was notified on 5 February 2024. This discrepancy arises from the structure of the Appendix 3H form, which can report cessations effective at future dates depending on the securities’ terms. Investors should note the cessation date as recorded in the official filing.

Under ASX Listing Rule 3.10.3E, companies must notify the market of employee incentive scheme security cessations within specified periods—five business days for key management personnel or associates, and ten business days after quarter-end for other holders. Bioxyne’s notification complies with these requirements. The announcement did not specify whether the lapsed rights’ holders were key management personnel or associates.

Bioxyne’s Remaining BXNAC Performance Rights After the Lapse

Following the lapse, Bioxyne’s capital structure shows 8,550,000 BXNAC Performance Rights still outstanding as unquoted equity securities. These remaining rights represent potential dilution if they vest and convert into fully paid ordinary shares, subject to their conditions. The lapse of this tranche indicates that some performance hurdles within the BXNAC series have not been met.

The company has not disclosed the vesting conditions, expiry dates, or holders of the remaining performance rights in this update. Such details are typically found in annual reports, remuneration reports, or future Appendix 3H filings if further cessations or conversions occur.

Unquoted Options on Issue Across Three Series Post-Update

In addition to the remaining performance rights, Bioxyne’s updated capital structure includes three series of unquoted options. The BXNAE series consists of 4,251,614 options exercisable at $0.50, expiring 26 March 2027. The BXNAF series includes 1,614,000 options with a $0.4375 exercise price, also expiring 26 March 2027. The BXNAG series comprises 106,450 options exercisable at $0.10, expiring on the same date.

These options represent potential future ordinary shares if exercised and if the company’s share price exceeds the respective exercise prices. The BXNAG options have the lowest strike price at $0.10, while BXNAE options have the highest at $0.50. The company did not disclose the current market price of BXN shares, and no immediate share price impact was evident from public information.

Current Quoted Ordinary Shares Total 229,977,671

After this cessation, Bioxyne’s total quoted ordinary shares stand at 229,977,671. This figure represents the fully paid ordinary share capital quoted on the ASX and is used to calculate the company’s market capitalisation. The lapse of performance rights does not alter the number of ordinary shares since lapsed rights are extinguished rather than converted.

The removal of 90,833 performance rights slightly reduces potential future dilution. Had these rights vested and converted, they would have increased the ordinary share count, diluting existing shareholders’ ownership. The company did not comment on the impact of this lapse on its broader capital management strategy.

Implications of Appendix 3H Filing for Investor Transparency

The Appendix 3H form is a mandatory disclosure under ASX Listing Rules, ensuring investors are informed of changes to securities issued under employee incentive schemes, including cessations. By submitting this form, Bioxyne fulfills its continuous disclosure obligations and provides an accurate view of its capital structure following the lapse of this BXNAC tranche.

For investors, Appendix 3H filings offer valuable insights into governance and incentive alignment. The lapse of a performance rights tranche may prompt questions about the performance conditions and whether Bioxyne’s operational or financial results fell short of targets. Bioxyne did not provide operational commentary in this update; investors may refer to recent quarterly activity reports or half-year financial statements for context.

Effect of the Lapse on Bioxyne’s Incentive Scheme

Performance rights-based incentive schemes are common among ASX-listed companies to align management with shareholder interests by linking remuneration to target achievement. The lapse of 90,833 BXNAC rights may indicate the scheme functioning as intended or that targets were set ambitiously relative to actual results.

Bioxyne did not disclose whether the lapsed rights were held by key management personnel or other participants, nor if replacement rights are planned. Detailed information on remuneration and incentives is typically found in the company’s annual remuneration report. Investors should watch for future Appendix 3H filings concerning the remaining 8,550,000 BXNAC Performance Rights.

Summary of Bioxyne’s Capital Structure After February 2024 Update

Following this update, Bioxyne’s capital structure includes 229,977,671 quoted ordinary shares, 8,550,000 unquoted BXNAC Performance Rights, and 5,972,064 unquoted options across the BXNAE, BXNAF, and BXNAG series. These unquoted securities represent potential future ordinary shares, contingent on performance conditions or option exercise.

Understanding both quoted and unquoted securities is vital for assessing dilution risk. The lapse of 90,833 performance rights is a modest absolute reduction relative to the total ordinary shares but confirms that this portion of the BXNAC rights will not convert into shares. Investors should continue monitoring quarterly and annual disclosures for updates on the remaining performance rights and options.

Key Disclosures for Investors to Monitor Going Forward

Investors tracking Bioxyne should watch for further Appendix 3H filings indicating additional cessations, lapses, or cancellations within the unquoted securities pool. Appendix 3B filings are also important, as they signal new securities issues, including any replacement performance rights or options granted under the company’s incentive schemes. Together, these filings provide detailed ongoing insights into changes in BXN’s capital structure.

Beyond capital structure, upcoming key milestones include Bioxyne’s next quarterly activities and cash flow reports, along with any operational or strategic updates. This company update contained no operational commentary, consistent with the administrative nature of the Appendix 3H cessation notice. The immediate impact on the share price was not apparent from publicly available information.